Spironolactone (MRA)
Treatment for Hypertensive Heart Disease
Typical Dosage: 12.5mg - 50mg daily
Effectiveness
89%
Safety Score
65%
Clinical Trials
500
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
12.5mg - 50mg daily
Time to Effect
Weeks for BP effect, months for mortality benefit
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$600
Side Effect Mgmt:$100
Total Annual:$730
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$8,000/QALY
QALYs Gained
3
Outcome-Based Costs
Cost per Responder
$1,123.08
Comparison vs Standard Therapy (without MRA)
Cost Difference
+$330/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Spironolactone (MRA) Outcomes
for Hypertensive Heart Disease
Efficacy Outcomes
Overall Effectiveness
+89%
Response Rate
+65%
Common Side Effects
Hyperkalemia
+15%
Gynecomastia
+10%
Dizziness
+5%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov